NYSEAMERICAN:ISR - IsoRay Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.39 0.00 (0.00 %)
(As of 04/21/2019 04:00 PM ET)
Previous Close$0.39
Today's Range$0.38 - $0.3998
52-Week Range$0.27 - $1.22
Volume43,469 shs
Average Volume171,741 shs
Market Capitalization$26.26 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is based in Richland, Washington.

Receive ISR News and Ratings via Email

Sign-up to receive the latest news and ratings for ISR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:ISR
Previous SymbolNYSEMKT:ISR
CUSIPN/A
Phone+1-509-3751202

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees38
Market Cap$26.26 million
Next Earnings Date5/2/2019 (Estimated)
OptionableNot Optionable

IsoRay (NYSEAMERICAN:ISR) Frequently Asked Questions

What is IsoRay's stock symbol?

IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

How were IsoRay's earnings last quarter?

IsoRay, Inc. (NYSEAMERICAN:ISR) released its quarterly earnings results on Tuesday, February, 12th. The healthcare company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). The healthcare company had revenue of $1.90 million for the quarter, compared to analysts' expectations of $1.76 million. View IsoRay's Earnings History.

When is IsoRay's next earnings date?

IsoRay is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for IsoRay.

What price target have analysts set for ISR?

2 brokerages have issued 12-month price targets for IsoRay's stock. Their predictions range from $1.00 to $2.00. On average, they anticipate IsoRay's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 284.6% from the stock's current price. View Analyst Price Targets for IsoRay.

What is the consensus analysts' recommendation for IsoRay?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IsoRay.

What are Wall Street analysts saying about IsoRay stock?

Here are some recent quotes from research analysts about IsoRay stock:
  • 1. According to Zacks Investment Research, "IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated. " (2/13/2019)
  • 2. Maxim Group analysts commented, "IsoRay reported the September quarter (FYE: June) with Cs-131 revenue of $1.56M, down 2.5% sequentially, and flat with the Dec and Mar quarters. The company ended the period with $9.2M in cash, including net proceeds of $8.25M from a July equity financing. Our fundamental view of Cs-131 is as a superior isotope for radio-therapy remains intact though IsoRay continues to struggle to drive revenue growth. It’s still early stage for Blu-Build and the question is can GammaTile be the answer? At this point it’s too early to tell and we see only incremental revenue growth. As such, we opt to step down to a Hold rating, from Buy, remove our price target." (11/9/2018)
  • 3. HC Wainwright analysts commented, "Our therapeutic models are patient-based, reflecting our assumptions for the market size, and share penetration rates and pricing. We use this to determine the future revenue streams. These metrics then flow into our valuation model." (9/26/2018)

Has IsoRay been receiving favorable news coverage?

Media stories about ISR stock have been trending neutral on Sunday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. IsoRay earned a news sentiment score of 0.4 on InfoTrie's scale. They also assigned headlines about the healthcare company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.

Are investors shorting IsoRay?

IsoRay saw a drop in short interest during the month of March. As of March 29th, there was short interest totalling 851,679 shares, a drop of 3.1% from the March 15th total of 878,845 shares. Based on an average daily volume of 85,516 shares, the days-to-cover ratio is presently 10.0 days. Approximately 1.3% of the shares of the company are sold short. View IsoRay's Current Options Chain.

Who are some of IsoRay's key competitors?

What other stocks do shareholders of IsoRay own?

Who are IsoRay's key executives?

IsoRay's management team includes the folowing people:
  • Ms. Lori A. Holmes-Woods, CEO & Director (Age 57)
  • Mr. Michael L. Krachon, VP of Sales & Marketing (Age 48)
  • Mr. William A. Cavanagh III, Chief R&D Officer (Age 53)
  • Mr. Jonathan R. Hunt, Co-Principal Financial Officer (Age 52)
  • Mr. Mark J. Austin CPA, Controller & Co-Principal Financial Officer (Age 32)

How do I buy shares of IsoRay?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IsoRay's stock price today?

One share of ISR stock can currently be purchased for approximately $0.39.

How big of a company is IsoRay?

IsoRay has a market capitalization of $26.26 million. IsoRay employs 38 workers across the globe.

What is IsoRay's official website?

The official website for IsoRay is https://isoray.com/.

How can I contact IsoRay?

IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.


MarketBeat Community Rating for IsoRay (NYSEAMERICAN ISR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about IsoRay and other stocks. Vote "Outperform" if you believe ISR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel